Table 5. Impact of BRCA1/2 P/LP variants on the DFS of breast cancer patients from subgroups of stage 0~II and III.
| P/LP variants | #Cases (events) | HR (95% CI) a | P a | Adjusted HR (95% CI) b | P b |
|---|---|---|---|---|---|
| Stage 0~II | |||||
| Germline and somatic variants combined | |||||
| Non-carrier | 287 (17) | 1 | 1 | ||
| BRCA1 | 15 (3) | 3.70 (1.08–12.76) | 0.04 | 2.06 (0.48–8.8) | 0.33 |
| BRCA2 | 21 (0) | 0 | 0.98 | 0 | 0.99 |
| Germline variants | |||||
| Non-carrier | 287 (17) | 1 | 1 | ||
| BRCA1 | 13 (3) | 4.52 (1.31–15.61) | 0.02 | 2.72 (0.65–11.44) | 0.17 |
| BRCA2 | 16 (0) | 0 | 0.98 | 0 | 0.99 |
| Somatic variants | |||||
| Non-carrier | 287 (17) | 1 | 1 | ||
| BRCA1/2 | 6 (0) | 0 | 0.66 | 0 | 1.00 |
| Stage III | |||||
| Germline and somatic variants combined | |||||
| Non-carrier | 93 (18) | 1 | 1 | ||
| BRCA1 | 4 (0) | 0 | 0.55 | 0 | 0.99 |
| BRCA2 | 6 (0) | 0 | 0.51 | 0 | 0.99 |
a Univariate Cox proportional hazards regression models
b Multivariate Cox proportional hazards regression models. HR was adjusted by age at diagnosis, molecular subtype (Luminal A, Luminal B, TNBC, HER2+ and ER-PR+), tumor grade (grade I/II and III) and administration of standard therapy.